• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种基于基质金属蛋白酶-2的列线图,用于评估腹膜透析患者包裹性腹膜硬化的风险。

A Matrix Metalloproteinase-2-Based Nomogram to Assess the Risk of Encapsulating Peritoneal Sclerosis in Peritoneal Dialysis Patients.

作者信息

Chou Che-Yi, Tseng Chin-Chung, Chen Jin-Bor, Hung Chin-Chuan, Huang Chiu-Ching

机构信息

College of Medicine, China Medical University, Taichung, Taiwan.

Division of Nephrology, Asia University Hospital, Taichung, Taiwan.

出版信息

Biomed Res Int. 2021 Jan 18;2021:6666441. doi: 10.1155/2021/6666441. eCollection 2021.

DOI:10.1155/2021/6666441
PMID:33532492
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7837760/
Abstract

BACKGROUND

Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication of peritoneal dialysis (PD). So far, there is no biomarker-based prediction tool available for EPS. Matrix metalloproteinase-2 (MMP-2) is a protein involved in the breakdown of the extracellular matrix, and the effluent MMP-2 can be a potential biomarker of EPS. This study is aimed at developing a nomogram for EPS based on effluent MMP-2 levels. . We enrolled 18 EPS patients and 90 gender-matched PD patients without EPS in this cross-sectional case-controlled study. The effluent MMP-2 levels and possible risk factors for EPS were analyzed using multivariable logistic regression, and a nomogram was developed. The nomogram was validated using 200 bootstrap resamples to reduce overfit bias.

RESULTS

The effluent MMP-2 levels in EPS patients were significantly higher than those in normal PD patients ( < 0.001, Manny-Whitney test). Effluent MMP-2 levels and PD duration were independently associated with EPS risks ( < 0.001 and = 0.001) in multivariate logistic regression. A nomogram based on MMP-2 levels and PD duration was proposed. The AUC of MMP-2 was 0.824, and the AUC of the nomogram was 0.907 ( = 0.05).

CONCLUSION

A nomogram based on effluent MMP-2 levels and PD duration may predict EPS with high accuracy.

摘要

背景

包裹性腹膜硬化(EPS)是腹膜透析(PD)一种罕见但严重的并发症。到目前为止,尚无基于生物标志物的EPS预测工具。基质金属蛋白酶-2(MMP-2)是一种参与细胞外基质分解的蛋白质,腹透液中的MMP-2可能是EPS的潜在生物标志物。本研究旨在基于腹透液MMP-2水平开发一种用于预测EPS的列线图。在这项横断面病例对照研究中,我们纳入了18例EPS患者和90例性别匹配的非EPS的PD患者。使用多变量逻辑回归分析腹透液MMP-2水平及EPS的可能危险因素,并绘制列线图。使用200次自抽样重采样对列线图进行验证以减少过度拟合偏差。

结果

EPS患者腹透液中MMP-2水平显著高于正常PD患者(Mann-Whitney检验,P<0.001)。在多变量逻辑回归中,腹透液MMP-2水平和PD持续时间与EPS风险独立相关(P<0.001和P = 0.001)。提出了一种基于MMP-2水平和PD持续时间的列线图。MMP-2的曲线下面积(AUC)为0.824,列线图的AUC为0.907(P = 0.05)。

结论

基于腹透液MMP-2水平和PD持续时间的列线图可能对EPS具有较高的预测准确性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bd2/7837760/692f56544c9f/BMRI2021-6666441.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bd2/7837760/8a168f772770/BMRI2021-6666441.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bd2/7837760/f3810c40e3c0/BMRI2021-6666441.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bd2/7837760/692f56544c9f/BMRI2021-6666441.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bd2/7837760/8a168f772770/BMRI2021-6666441.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bd2/7837760/f3810c40e3c0/BMRI2021-6666441.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bd2/7837760/692f56544c9f/BMRI2021-6666441.003.jpg

相似文献

1
A Matrix Metalloproteinase-2-Based Nomogram to Assess the Risk of Encapsulating Peritoneal Sclerosis in Peritoneal Dialysis Patients.一种基于基质金属蛋白酶-2的列线图,用于评估腹膜透析患者包裹性腹膜硬化的风险。
Biomed Res Int. 2021 Jan 18;2021:6666441. doi: 10.1155/2021/6666441. eCollection 2021.
2
Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis.包裹性腹膜硬化症中的腹腔渗出液 MMP-2 和 PAI-1。
Am J Kidney Dis. 2015 May;65(5):748-53. doi: 10.1053/j.ajkd.2014.10.022. Epub 2014 Dec 17.
3
The peritoneal sieving of sodium: a simple and powerful test to rule out the onset of encapsulating peritoneal sclerosis in patients undergoing peritoneal dialysis.腹膜筛钠:一项简单而强大的测试,可排除腹膜透析患者发生包裹性腹膜硬化症。
J Nephrol. 2018 Feb;31(1):137-145. doi: 10.1007/s40620-016-0371-9. Epub 2016 Dec 24.
4
The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan.基质金属蛋白酶-2作为腹膜损伤、溶质转运增加或腹膜透析期间发展为包裹性腹膜硬化标志物的潜力——日本一项多中心研究
Nephrol Dial Transplant. 2007 Feb;22(2):560-7. doi: 10.1093/ndt/gfl566. Epub 2006 Oct 11.
5
Recent Understanding and Future Directions in the Application of MMP-2 in Encapsulating Peritoneal Sclerosis Clinical Practice.MMP-2 在包裹性腹膜硬化临床应用中的最新认识与未来方向。
Blood Purif. 2023;52(4):359-365. doi: 10.1159/000528001. Epub 2023 Jan 4.
6
What does the dialysate level of matrix metalloproteinase 2 tell us?基质金属蛋白酶2的透析液水平能告诉我们什么?
Adv Perit Dial. 2011;27:6-10.
7
Risk factors for encapsulating peritoneal sclerosis in long-term peritoneal dialysis: a retrospective observational study.长期腹膜透析中包裹性腹膜硬化的危险因素:一项回顾性观察研究。
Ther Apher Dial. 2014 Feb;18(1):68-73. doi: 10.1111/1744-9987.12048. Epub 2013 Apr 17.
8
Risk factors and clinical outcomes of encapsulating peritoneal sclerosis: A case-control study from China.包裹性腹膜硬化症的风险因素和临床结局:来自中国的病例对照研究。
Perit Dial Int. 2022 Sep;42(5):505-512. doi: 10.1177/08968608211029224. Epub 2021 Jul 14.
9
Early Detection of Imminent Encapsulating Peritoneal Sclerosis: Free Water Transport, Selected Effluent Proteins, or Both?即将发生的包裹性腹膜硬化的早期检测:自由水转运、特定腹水蛋白,还是两者兼用?
Perit Dial Int. 2019 Jan-Feb;39(1):83-89. doi: 10.3747/pdi.2017.00194. Epub 2018 Nov 25.
10
Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients?在腹膜透析患者中,流出液基质金属蛋白酶 2 和纤溶酶原激活物抑制剂 1 可否作为腹膜膜改变的生物标志物?
Perit Dial Int. 2013 Sep-Oct;33(5):529-37. doi: 10.3747/pdi.2012.01063. Epub 2013 Sep 1.

本文引用的文献

1
Calculating the sample size required for developing a clinical prediction model.计算开发临床预测模型所需的样本量。
BMJ. 2020 Mar 18;368:m441. doi: 10.1136/bmj.m441.
2
Incidence and outcomes of encapsulating peritoneal sclerosis (EPS) and factors associated with severe EPS.包裹性腹膜硬化症(EPS)的发病率、结局及与严重EPS相关的因素
PLoS One. 2018 Jan 2;13(1):e0190079. doi: 10.1371/journal.pone.0190079. eCollection 2018.
3
A prospective, proteomics study identified potential biomarkers of encapsulating peritoneal sclerosis in peritoneal effluent.
一项前瞻性的蛋白质组学研究鉴定出腹水中包裹性腹膜硬化症的潜在生物标志物。
Kidney Int. 2017 Oct;92(4):988-1002. doi: 10.1016/j.kint.2017.03.030. Epub 2017 Jul 1.
4
Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study.腹膜炎症先于包裹性腹膜硬化症:全球液体研究结果
Nephrol Dial Transplant. 2016 Mar;31(3):480-6. doi: 10.1093/ndt/gfv440. Epub 2016 Jan 26.
5
Interstitial Fibrosis Restricts Osmotic Water Transport in Encapsulating Peritoneal Sclerosis.间质纤维化限制包裹性腹膜硬化症中的渗透性水转运。
J Am Soc Nephrol. 2015 Oct;26(10):2521-33. doi: 10.1681/ASN.2014090939. Epub 2015 Jan 30.
6
Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis.包裹性腹膜硬化症中的腹腔渗出液 MMP-2 和 PAI-1。
Am J Kidney Dis. 2015 May;65(5):748-53. doi: 10.1053/j.ajkd.2014.10.022. Epub 2014 Dec 17.
7
Interleukin-6 signaling drives fibrosis in unresolved inflammation.白细胞介素-6 信号转导驱动未解决炎症中的纤维化。
Immunity. 2014 Jan 16;40(1):40-50. doi: 10.1016/j.immuni.2013.10.022. Epub 2014 Jan 9.
8
Current status and practical use of effluent biomarkers in peritoneal dialysis patients.腹膜透析患者的排泄生物标志物的现状和实际应用。
Am J Kidney Dis. 2013 Oct;62(4):823-33. doi: 10.1053/j.ajkd.2013.01.031. Epub 2013 May 11.
9
The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made.腹膜渗透电导早在诊断出包裹性腹膜硬化症之前就已经很低了。
Kidney Int. 2010 Sep;78(6):611-8. doi: 10.1038/ki.2010.186. Epub 2010 Jun 23.
10
Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes.包裹性腹膜硬化症:发病情况、预测因素和结局。
Kidney Int. 2010 May;77(10):904-12. doi: 10.1038/ki.2010.16. Epub 2010 Mar 10.